REVLIMID(R) Evaluated in Combination with Rituximab as a Potential Treatment ... MarketWatch (press release) The multicenter phase II study enrolled 69 patients and evaluated the efficacy and safety of combination therapy with lenalidomide and rituximab in untreated patients with chronic lymphocytic leukemia. Forty patients less than 65 years of age were ... Celgene Unit Releases Final Phase 2 Data Evaluating REVLIMID and Rituximab (CELG) Final Phase II Data Evaluating REVLIMID and Rituximab in Patients with ... |
